Urologix targets wider BPH (benign prostatic hyperplasia) market:
This article was originally published in Clinica
Urologix has released a version of its Cooled ThermoTherapy treatment for benign prostatic hyperplasia (BPH) that will allow it to target its therapy to more patients, the Minneapolis, Minnesota firm reports. The new product comprises a shorter length catheter designed to treat the estimated 15-20% of patients that have smaller prostates and will complement the firm's standard catheter, which is indicated for patients with medium to larger prostates. Cooled ThermoTherapy delivers microwave energy into the prostate while using a cooling process that minimises the effect on surrounding tissue.